Therapeutic strategies for gastrointestinal stromal tumors

Stomach and Intestine

Volumn 36, Issue 9, 2001, Pages 1174-1175

  Otani, Yoshihide ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012003688     PISSN: 05362180     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol 30: 1213-1220, 1999
2. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 231 : 51-58, 2000
3. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine : A review of 50 cases from a prospective database. Ann Surg Oncol 8: 50-59, 2001
4. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site. Am J Surg Pathol 23: 82-87, 1999
5. Kwon SJ, Members of the Korean Gastric Cancer Study Group. Surgery and prognostic factors for gastric stromal tumor. World J Surg 25: 290-295, 2001
6. Yoshida M, Otani Y, Ohgami M, et al. Surgical management of gastric leiomyosarcoma: Evaluation of the properiety of laparoscopic wedge resection. World J Surg 21: 440-443, 1997
7. Shiu MH, Farr GH, Papachristou DN, et al. Myosarcoma of the stomach : Natural history, prognostic factors and management. Cancer 49: 177-187, 1982
8. Grant CS, Kim CH, Farrugia G, et al. Gastric leiomyosarcoma - Prognostic factors and surgical management. Arch Surg 126: 985-990, 1991
9. Otani Y, Ohgami M, Igarashi N, et al. Laparoscopic wedge resection of gastric submucosal tumors. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 10: 19-23, 2000
10. Ohgami M, Otani Y, Kumai K, et al. Curative laparoscopic surgery for early gastric cancer : Five years experience. World J Surg 23: 187-193, 1999
11. JSES 2: 219, 1997
12. Otani Y, Ohgami M, Kitajima M. Haemostatic dissection devices : Today's clinical experience and future options. Min Invas Ther &; Allied Technol 8: 69-72, 1999
13. Miettinen M, Virolainen M, Rikala MS. Gastrointestinal stromal tumors - Value of CD34 antigen in their identification and separation from true leiomyomas and Schwannomas. Am J Surg Pathol 19: 207-216, 1995
14. Tio TL, Tytgat GNJ, den Hartog Jager FCA. Endoscopic ultrasonography for the evaluation of smooth muscle tumors in the upper gastrointestinal tract: an experience with 42 cases. Gastrointest Endosc 36 : 342-350, 1990
15. Gastroentrol Endosc 37: 566-571, 1995
16. Watanabe H, Jass JR, Sobin LH. Histological Typing of Oesophageal and Gastric Tumours, 2nd ed. Springer-Verlag, Berlin, pp 28-29, 1990
17. Newman PL, Wadden C, Fletcher CDM. Gastrointestinal stromal tumors - Correlation of immunophenotype with clinicopathological features. J Pathol 164: 107-117, 1991
18. Amin MB, Ma CK, Linden MD, et al. Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors. Crrelation with mitotic count and clinical outcome. Am J Clin Pathol 100: 428-432, 1993
19. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59: 4297-4300, 1999
20. Nishida T, Nakamura J, Taniguchi M, et al. Clinicopathological features of gastric stromal tumors. J Exp Clin Cancer Res 19: 417-425, 2000
21. Yamaguchi M, Miyaki M, Iijima T, et al. Specific mutation in exon 11 c-kit proto-oncogene in a malignant gastrointestinal stromal tumor of the rectum. J gastroenterol 35: 779-783, 2000
22. Ballarini C, Intra M, Ceretti AP, et al. Gastrointestinal stromal tumors: a "benign" tumor with hepatic metastasis after 11 years. Tumori 84 : 78-81, 1998
23. Katai H, Sasako M, Sano T, et al. Wedge resection of the stomach for gastric leiomyosarcoma. Br J Surg 84: 560-561, 1997
24. Abstract # 1, 37th Annual Meeting of ASCO, 2001
25. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996
26. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3- 7, 2000
27. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumors. N Engl J Med 344: 1052-1056, 2001